Registry Experience at the Washington Hospital Center, DES - Endeavor for Myocardial Infarction

Interventional cardiology was revolutionized by the invention of stents, initially with the
bare-metal stents (BMS) and recently with the drug-eluting stents (DES).Zotarolimus-eluting
stents have shown promising results in randomized clinical trails, demonstrating a reduction
of clinical and angiographic restenosis in comparison to BMS, and comparable
clinically-driven target lesion revascularization rates in comparison with Sirolimus-eluting
stents. While short-term and 1 year registry data is available from outside of the United
States, it will be important to collect "real-world" data regarding the stent usage and
outcomes in the United States. In this study we propose to follow patients who received at
least one Endeavor® Stent as primary treatment for ACS for up to 3 years post initial stent
implantation.

Inclusion Criteria:

- Patients, male or female, >18 years of age

- Patients presenting with acute coronary syndrome (ACS), where ACS is defined as
ST segment deviation of >1mm or an elevation of the isoenzymes greater than 2x upper
limit of normal

- Patients who received at least one Endeavor drug-eluting stent at the Washington
Hospital Center

Exclusion Criteria:

- N/A